🔍

ALKALI - Alkali Metals

📊 NSE: ALKALI 🏢 Chemicals 📅 Last Updated: 12/13/2025 18:08

📢 Recent Corporate Announcements

Alkali Metals Q3 Revenue Up 11.5% YoY to ₹24.9 Cr; Net Loss Narrows to ₹1.39 Cr

🔵 WATCH ⭐ 6/10

EARNINGS 📅 14 Feb 2026, 12:18 PM

Alkali Metals Limited reported a revenue of ₹24.91 crore for the quarter ended December 31, 2025, an 11.5% increase from ₹22.34 crore in the same quarter last year. The company's net loss narrowed significantly on a year-on-year basis to ₹1.39 crore, compared to a loss of ₹4.93 crore in Q3 FY25. A notable shift in geographical performance was observed, with domestic revenue surging 155% YoY to ₹16.09 crore, while export revenue declined by 45% to ₹8.82 crore. Despite the YoY improvement, the net loss widened sequentially from ₹0.91 crore in Q2 FY26.

Revenue from operations grew 11.5% YoY to ₹24.91 crore in Q3 FY26.
Net loss for the quarter narrowed to ₹1.39 crore from ₹4.93 crore in the previous year's corresponding quarter.
Domestic sales saw a massive jump to ₹16.09 crore from ₹6.30 crore YoY, offsetting weak export performance.
For the nine-month period ended Dec 2025, the net loss reduced to ₹3.46 crore from ₹10.15 crore in the previous year.
Finance costs rose to ₹69.17 lakhs in Q3 FY26 compared to ₹49.79 lakhs in Q3 FY25.

💡 Investors should remain cautious as the company continues to be loss-making despite the narrowing of losses and strong domestic growth. Monitor if the company can sustain its domestic momentum and manage rising finance costs to achieve break-even in the coming quarters.

Alkali Metals Submits SEBI Reg 74(5) Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 21 Jan 2026, 05:03 PM

Alkali Metals Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by Registrar Cameo Corporate Services Limited, confirms that all dematerialization requests for the quarter ended December 31, 2025, were processed correctly. It verifies that physical share certificates were mutilated and cancelled within the mandatory 15-day period. This filing is a standard administrative procedure to ensure the accuracy of the company's shareholding records.

Compliance certificate submitted for the quarter ended December 31, 2025
Registrar Cameo Corporate Services confirmed dematerialization requests were processed and listed
Physical certificates were mutilated and cancelled within the required 15-day timeframe
Depository names were substituted in the Register of Members as registered owners

💡 No action is required from investors as this is a routine regulatory filing confirming administrative compliance.

Alkali Metals Announces Trading Window Closure from Jan 1 for Q3 FY26 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 31 Dec 2025, 11:49 AM

Alkali Metals Limited has notified the exchanges regarding the closure of its trading window for designated persons starting January 1, 2026. This action is in accordance with SEBI Prohibition of Insider Trading Regulations for the upcoming Q3 FY 2025-26 financial results. The window will remain closed until 48 hours after the results for the quarter ending December 31, 2025, are declared. The company will announce the specific date for the board meeting to approve these results in a separate filing.

Trading window closure starts on January 1, 2026.
Closure is for the third quarter (Q3) financial results of FY 2025-26.
Window remains shut until 48 hours post-result declaration.
Applies to Promoters, Directors, KMP, and other designated persons.

💡 This is a standard regulatory announcement; no action is needed. Investors should wait for the Q3 earnings release to assess the company's financial health.

View All ALKALI Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The company's revenue was Rs. 82.3 crore in FY2025, a slight decrease of 0.7% from Rs. 82.9 crore in FY2024. Sodium derivatives remain the major product category, though specific percentage growth per segment was not disclosed.

Geographic Revenue Split

Exports account for the majority of total revenue. The company plans to expand its presence to over 30 countries by 2027, including Eastern Europe and China, with a specific target of $1 million (Rs. 8.6 crore) from the Chinese market by 2027.

Profitability Margins

Profitability has been under significant pressure, with the company reporting an operating loss in FY2025 and H1 FY2025. For the half-year ended September 30, 2025, the company reported a total comprehensive loss before tax of Rs. 0.59 crore compared to a loss of Rs. 5.33 crore in the previous year.

EBITDA Margin

The EBITDA margin was negative in FY2025 due to lower spreads between selling prices and raw material costs for sodium derivatives and amino pyridines. However, the company reported an operating profit in Q4 FY2025 after three consecutive quarters of losses.

Capital Expenditure

The company incurred Rs. 0.32 crore (Rs. 31.71 lakhs) in property, plant, and equipment purchases for the half-year ended September 30, 2025, compared to Rs. 0.18 crore in the same period of 2024. Maintenance capex is ongoing.

Credit Rating & Borrowing

ICRA reaffirmed the long-term rating at [ICRA]BB+ and short-term at [ICRA]A4+, but revised the outlook to Negative. Interest coverage below 2.3 times on a sustained basis is a trigger for a further downgrade.

⚙️ Operational Drivers

Raw Materials

Key raw materials include Sodium Metal and Pyridine, which are critical for the production of sodium derivatives and pyridine derivatives.

Import Sources

The company primarily imports its key raw materials, sodium metal and pyridine, to support its manufacturing processes.

Capacity Expansion

The Visakhapatnam unit, started in 2011-2012 for APIs and fine chemicals, continues to operate at significantly low capacity utilization, which has historically constrained revenue growth.

Raw Material Costs

Raw material costs are a major driver of profitability; lower spreads between raw material costs and selling prices led to operating losses in FY2025.

Manufacturing Efficiency

Efficiency is currently low due to underutilization of the Visakhapatnam facility and long processing times involved in multi-stage manufacturing.

📈 Strategic Growth

Expected Growth Rate

12-15%

Growth Strategy

Growth will be driven by expanding the product portfolio with new molecules, increasing the buyer network across 30+ countries by 2027, and specifically targeting the Chinese market for $5 million (Rs. 43.42 crore) in revenue by 2030.

Products & Services

Sodium derivatives (Sodium Amide, Sodium Azide, Sodium Hydride), Pyridine derivatives (Amino Pyridines), Fine Chemicals, and Active Pharmaceutical Ingredients (APIs).

Brand Portfolio

Alkali Metals Limited (B2B operations).

New Products/Services

The company is focusing on developing new molecules and expanding its product portfolio to improve margins, though specific revenue contribution percentages for new launches were not disclosed.

Market Expansion

Targeting expansion into Eastern Europe and China by 2027, with a goal to reach 30 countries.

Strategic Alliances

The company was originally set up in 1968 as a joint venture with Andhra Pradesh Industrial Development Corporation Limited (APIDCL).

🌍 External Factors

Industry Trends

The Indian Pharmaceutical Market is projected to reach $130 billion by 2030, while the global market is expected to hit $1.7 trillion. The sector currently contributes 1.8% to India's GDP.

Competitive Landscape

The industry is characterized by cyclical demand and pricing volatility in principal markets, with competition affecting the spreads of sodium and pyridine derivatives.

Competitive Moat

The company possesses a durable advantage through its 30-year track record in manufacturing specialized sodium derivatives, which are technically complex to produce.

Macro Economic Sensitivity

Highly sensitive to global geo-political conflicts and economic downturns, which caused macro headwinds and disruptions in the recent annual performance.

Consumer Behavior

Not applicable as the company operates in the B2B pharmaceutical and chemical intermediate space.

Geopolitical Risks

Trade barriers and disruptions from geo-political conflicts are cited as major hurdles to sustaining growth and navigating complex business environments.

⚖️ Regulatory & Governance

Industry Regulations

Operations are subject to chemical manufacturing standards and pollution norms; the company maintains manufacturing controls as a key monitorable for its credit rating.